• Study reports abnormally high VTE and high bleed risk in critically ill COVID-19 patients and calls for more effective prevention strategies.
  • Clinicians at NHS hospitals are supporting the care of COVID-19 patients with the use of geko™ devices to reduce the risk of blood clots in the most at risk patients.
Learn more Contact us

Firstkind to Showcase First New Approach to Prevent DVT in Immobile Stroke Patients in 20 Years at ISC 2020


The geko™ device now in routine use across multiple UK NHS hospitals and internationally.

HIGH WYCOMBE, EnglandFeb. 14, 2020 /PRNewswire/ — Firstkind Ltd, a UK-based medical devices company and subsidiary of Sky Medical technology Ltd, has today announced attendance at the International Stroke Conference (ISC), Los AngelesFebruary 19 –21, to showcase the geko™ device, the first and only bioelectronic muscle pump activator of its kind to be cleared by the FDA for stimulation of the calf muscles to prevent VTE across all patients, including non-surgical patients – and a first new approach in 20 years.


As well as exhibiting (booth #239, Exhibit Floor), Firstkind will host a Learning Studio, booth #155, on Thursday 20th February at 1:00pm to 1:30pm. Titled: Optimal VTE Prophylaxis in Stroke Patients: Practical Challenges and New Solutions, the session will cover:


  • Current US post-stroke VTE prophylaxis
  • VTE prophylaxis strategies when anticoagulant and/or SCDs cannot be prescribed
  • And real-world data demonstrating zero VTEs in patients prescribed the geko™ device
  • ISC delegates can register through this link: https://www.vtestroke.com

Commenting, Sky/Firstkind Founder and CEO Bernard Ross said “We are excited to attend the ISC 2020. It coincides with a transformational time for our company as we further extend and accelerate our FDA clearances and clinical milestones for US market entry. Our bioelectronic technology platform, OnPulse™, embedded in the geko™ device, completely redefines the way life threatening blood clots can now be prevented and vascular conditions treated.”

He adds, “A recent study of the geko™ device to prevent VTE in acute stroke patients reported zero VTEs in patients prescribed the geko™ device alone. These findings have accelerated geko™ adoption across multiple UK NHS hospitals and internationally, providing patients with an alternative option where current standards of care are contraindicated or impractical.”

The geko™ device is a non-invasive, easy to use, wearable therapy device. The size of a wristwatch and worn at the knee, the daily disposable device gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, resulting in increased blood flow in the deep veins of the calf. The geko™ device operates without external pressure to the leg and allows complete mobility.

The Company has U.S. Food & Drug Administration (FDA) 510(k) clearances to market the geko™ device for: stimulation of the calf muscles to prevent venous thrombosis in non-surgical patients at risk for venous thromboembolism; immediate post-surgical stimulation of calf muscles to prevent VTE, increasing blood circulation and edema reduction.